Generalized Anxiety Disorder Adjunct Study

Study identifier:D1441L00016

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Multicenter, Rand., Double-blind, Parallel-group, Pbo-controlled Study of the Efficacy and Safety of SEROQUEL® XR Compared with Pbo as an Adjunct to Treatment in Patients with Generalized Anxiety Disorder who Demonstrate Partial or No Response to a SSRI or SNRI Alone or in Combination with a Benzo

Medical condition

Anxiety

Phase

Phase 3

Healthy volunteers

No

Study drug

Placebo, quetiapine fumarate XR

Sex

All

Actual Enrollment

409

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 01 Aug 2007
Primary Completion Date: 01 Sept 2008
Study Completion Date: 01 Sept 2008

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Apr 2011 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria